

1 year and 21–38% after 2 years.<sup>156,157</sup> Switching therapy from LVD to ADV may enhance the acquisition of another mutation and induce replication of HBV DNA.<sup>158–160</sup> On the other hand, combination therapy of LVD and ADV effectively suppressed viral replication and maintained high efficacy in LVD-resistant patients with chronic HBV infection.

## ETV

Entecavir is a guanine analogue and Chang *et al.* have reported that ETV is effective in reducing the serum level of HBV DNA compared with LVD in HBeAg positive patients (Table 2).<sup>159</sup> The cumulative proportion of patients with undetectable HBV DNA (<300 copies/mL) increased to 81% after 1 year of therapy and 93% after 5 years of therapy.<sup>160</sup> After 1 year of treatment with ETV, the serum ALT level was normalized in approximately 70% of patients, and increased to 90% of patients after 5 years. Lai *et al.* have reported that ETV is more efficacious in HBeAg negative patients compared with LVD (Table 2).<sup>161</sup> ETV is the most potent of the currently available anti-HBV drugs because it affects multiple functions of the polymerase, including priming, reverse transcription and DNA elongation.<sup>162</sup>

Entecavir was licensed for the treatment of chronic hepatitis B in Japan in 2006. In nucleos(t)ide-naïve patients, ETV is given at dose of 0.5 mg/day.


The rate of ETV resistance was extremely low in nucleoside-naïve patients.<sup>160,163,164</sup> The incidence of ETV resistance in nucleos(t)ide analogue-naïve patients was reported to be 1.2% at 3 years (Fig. 1).<sup>160,163,164</sup> HBeAg loss was observed in 8% of these patients. The response to ETV was lower in LVD-resistant patients than in nucleos(t)ide analogue-naïve patients. In LVD-resistant patients, 20% of patients had undetectable HBV DNA levels after 48 weeks of ETV therapy, and the resistance rate to ETV was 26% at 3 years. Patients with HBeAg at the initiation of ETV had a resistance rate to ETV of 36% at 3 years. On the other hand, patients without HBeAg at the initiation of ETV did not have resistance to ETV at 3 years (Fig. 2).<sup>160,165</sup> In LVD-resistant patients, the risk of the development of resistance to ETV is much higher than those without LVD resistance.<sup>160,165</sup>

The resistance to ETV is principally associated with the mutations rtM250V, rtI169T or rtS202I in addition to the primary LVD resistance mutations rtM204V + rtL180M. The need for multiple mutations to induce ETV resistance suggests a higher genetic barrier to resistance and explains the low rate of resistance to ETV in nucleos(t)ide analogue-naïve patients.

Table 2 Efficacy of nucleoside analogues for chronic hepatitis B

		Subject: HBeAg positive patients <sup>159</sup>					
	n	Change of HBV DNA (log copies/mL)	Negativity of HBV DNA of <300 copies/mL	Normalization of ALT	SC		
ETV 0.5 mg	354	-6.9	67%	P < 0.001	68%	P < 0.05	21%
LVD 100 mg	355	-5.4	36%	P < 0.001	60%		18%
		Subject: HBeAg negative patients <sup>161</sup>					
	n	Change of HBV DNA (log copies/mL)	Negativity of HBV DNA of <300 copies/mL	Normalization of ALT			
ETV 0.5 mg	325	-5.0	90%	P < 0.001	78%	P < 0.05	
LVD 100 mg	323	-4.5	72%	P = 0.001	71%		

ALT, alanine aminotransferase; ETV, entecavir; HBeAg, hepatitis B e-antigen; HBV, hepatitis B virus; LVD, lamivudine; SC, seroconversion; VR, virological response.



**Figure 2** Cumulative development rate of mutant virus after the initiation of entecavir monotherapy in hepatitis B patients with resistance after the administration of lamivudine monotherapy.<sup>164</sup> (a) Cumulative development rate of mutant virus in all patients. (b) Cumulative development rate of mutant virus based on the difference of hepatitis B patients with positive hepatitis B e-antigen (HBeAg) and hepatitis B patients with negative HBeAg.

#### Consensus 9

Drug-resistant virus with specific mutations in the polymerase/reverse transcriptase gene emerges during nucleos(t)ide analogue therapy in chronic hepatitis B patients. The rtM204V/I and rtL180M mutations are associated with LVD resistance, the rtN236T and rtI233V or rtA181V with ADV resistance, and the rtM250V or rtT184G or rtS202I combined with rtM204V + rtL180M with ETV resistance. (Level 4, grade C.)

#### Recommendation 6

When patients with chronic hepatitis B are treated with nucleos(t)ide analogues, ETV should be given as the first-line drug because of its high efficacy and low emergence of viral resistant mutant. (Level 1b, grade A.)

#### Recommendation 7

The combination therapy of LVD and ADV is an effective treatment for LVD-resistant patients. (Level 1b, grade B.)

## INTERFERON THERAPY FOR CHRONIC HEPATITIS B

**I**NTERFERON (IFN) WAS the first antiviral treatment approved for chronic HBV infection. IFN- $\alpha$  and - $\beta$

have a predominantly antiviral effect but also have an immunomodulatory effect and antiproliferative effect which is in contrast to direct antiviral agents such as nucleos(t)ide analogues. The duration of treatment is defined (usually 24–48 weeks) in IFN therapy. This finite duration of therapy is an advantage over direct antiviral agents which are usually given indefinitely. The long-term outcome of therapy is more precisely described in IFN compared to LVD due to its longer history of clinical usage.

### Selection of patients

Factors associated with favorable response to IFN therapy are vigorously studied (Table 3). For HBeAg positive patients, high pretreatment ALT levels,<sup>166</sup> high grade of necroinflammation on liver histology and low serum HBV DNA level have consistently been shown to be predictive of favorable response.<sup>167</sup> Other predictive factors include female sex,<sup>166</sup> younger age,<sup>168,169</sup> and HBV genotype A versus D or B versus C.<sup>169,170</sup> Patients fulfilling these predictors are the best candidates for IFN treatment. For HBeAg negative patients, there is no consistent predictor of response. Adverse events such as severe infection or exacerbations of liver disease were common when IFN was given for decompensated cirrhosis. Thus, patients with decompensated cirrhosis should not be treated with IFN due to a risk of precipitating hepatic failure and fatal complications.<sup>171,172</sup>

**Table 3** Predictive factors for response to interferon therapy

Predictive factors	HBeAg positive	HBeAg negative
Race	No correlation	No correlation
Age	No correlation or Younger	No correlation or Younger
Sex	No correlation or Female	No correlation or Female
ALT	Higher level	No correlation or Higher level
Activity	Higher grade	No correlation
Fibrosis	Conflicting	No correlation
HBV DNA titer	Lower titer	No correlation or lower titer
Genotype	A > D, B > C	A > D, B > C
Precore	Conflicting	No correlation
Core promoter	mutant	

ALT, alanine aminotransferase; HBeAg, hepatitis B e-antigen; HBV, hepatitis B virus.

**Recommendation 8**

Younger age, high ALT levels, low HBV load, genotype A or B and high inflammatory activity in liver biopsy are predictive of good response to IFN. IFN therapy should be considered in patients fulfilling these predictors. (Level 2a, 2b, grade B.)

**Recommendation 9**

Interferon should be avoided for patients with decompensated cirrhosis. (Level 4, grade D.)

**Standard IFN therapy in HBeAg positive chronic hepatitis B**

A meta-analysis of 16 randomized controlled studies have shown that treatment with IFN- $\alpha$  for 16–24 weeks versus an untreated control is associated with higher rate of HBeAg loss (33% vs 12%), HBeAg seroconversion (difference of 18%), undetectable HBV DNA by hybridization or branched chain assay (37% vs 17%), HBsAg loss (7.8% vs 1.8%) and ALT normalization (difference of 23%) (Table 4).<sup>173</sup> A controlled trial has shown that extending therapy for up to 32 weeks in patients who remained HBeAg positive at the end of 16 weeks of

therapy improved the rate of HBeAg seroconversion.<sup>174</sup> The durability of HBeAg seroconversion is more than 80%, and even delayed seroconversion could occur in 10–15% of patients 1–2 years after completion of therapy.<sup>175–177</sup> The loss of HBsAg is reported to occur in 12–65% of patients who cleared HBeAg.<sup>175,178</sup> However, this is a rare event in Asian patients.<sup>176,177</sup>

**Consensus statement 10**

10-1 In HBeAg positive patients, treatment with IFN versus untreated control is associated with higher rate of HBeAg loss, HBeAg seroconversion, undetectable HBV DNA, HBsAg loss and ALT normalization. Extension of therapy improves the rate of HBeAg seroconversion. (Level 1a,1b.)

10-2 Durability of HBeAg seroconversion is more than 80%. The loss of HBsAg is rare in Asian patients. (Level 1b.)

**Standard IFN therapy in HBeAg negative chronic hepatitis B**

Although the rate of response at the end of therapy is 60–90%, the durability of long-term response is less

**Table 4** Standard interferon therapy for HBeAg positive chronic hepatitis B. Meta-analysis of 16 randomized controlled trials

	Interferon	Control	P-value
Loss of HBV DNA	37%	17%	0.0001
Loss of HBeAg	33%	12%	0.0001
Loss of HBsAg	7.8%	1.8%	0.001
Seroconversion		Difference of 18%	0.002
ALT normalization		Difference of 23%	0.0001

ALT, alanine aminotransferase; HBeAg, hepatitis B e-antigen; HBV, hepatitis B virus.

than 50%.<sup>179,180</sup> Longer duration of therapy is associated with improved durability of response: 10-15% with 4-6 months of therapy, 22-30% with 6-12 months of therapy and 30% with 24 months of therapy.<sup>181-184</sup>

#### Consensus statement 11

11-1 Durability of response is less than 50% in HBeAg negative patients. (Level 1b.)

11-2 Longer duration of therapy (>48 weeks) is associated with improved durability of response. (Level 2b.)

### Pegylated IFN (PEG IFN)

Twenty four weeks of PEG IFN- $\alpha$ -2a monotherapy had higher rate of combined response (loss of HBeAg, suppression of HBV DNA <500 000 copies/mL and ALT normalization) compared to standard IFN- $\alpha$ -2a.<sup>185</sup> Another study with 24 weeks of PEG IFN- $\alpha$ -2b monotherapy also showed a higher rate of HBeAg loss and HBV DNA suppression compared to standard IFN- $\alpha$ -2b.<sup>169</sup>

Controlled studies comparing the 48 weeks of PEG IFN- $\alpha$ -2a and LVD in HBeAg positive and negative patients revealed that PEG IFN had a higher rate of sustained response.<sup>170,171</sup> Seroconversion of HBeAg (32% vs 19%), ALT normalization (41% vs 28% in HBeAg positives and 59% vs 44% in HBeAg negatives), HBV DNA suppression (HBV DNA <10 000 copies/mL, 32% vs 22% in HBeAg positives; HBV DNA <20 000 copies/mL, 43% vs 29% in HBeAg negatives) and negative HBV DNA (14% vs 5% in HBeAg positives and 19% vs 7% in HBeAg negatives) were more frequent in PEG IFN treated patients.

Differences were reported in outcome of the antiviral treatment of patients infected with different genotypes; genotype B is associated with a higher rate of antiviral response to IFN treatment than HBV genotype C among Asian patients with HBeAg positive chronic hepatitis B.<sup>169,186,187</sup> In multicenter trials comparing combination therapy of PEG IFN- $\alpha$ -2b and LVD versus PEG IFN- $\alpha$ -2b alone, it was shown that treatment with PEG IFN- $\alpha$ -2b is the best therapy to achieve HBSAg clearance in patients with genotype A compared with D.<sup>188,189</sup>

### Combination or sequential therapy

Combination of two antiviral agents with different mechanisms of action seems a logical approach to improve efficacy. In fact, simultaneous combination of LVD and PEG IFN has a higher rate of HBV suppression, ALT normalization and less frequent emergence of LVD-resistant mutant virus compared to LVD alone. However, there is no difference in treatment response between the simultaneous combination of LVD and IFN or PEG IFN compared to IFN or PEG IFN alone (Table 5).<sup>132,133,170</sup>

There are several clinical trials of sequential therapy with LVD followed by IFN.<sup>190-194</sup> Common to all studies is that the sequential therapy had no advantage over IFN alone. Some studies have shown the suggestive evidence that sequential therapy had a higher rate of HBV suppression, ALT normalization and less frequent emergence of LVD-resistant mutant virus compared to LVD alone (Table 5).<sup>190-194</sup> However, because the study protocols and their results are variable, a conclusive result could not be drawn.

Table 5 Sequential therapy of lamivudine and interferon

		BR	SC	VR	LVD-R
Manesis <i>et al.</i> 2006 (n = 36) <sup>190</sup>	Sequential	39%	NA	28%	
	IFN	22%	NA	19%	
Shi <i>et al.</i> 2006 (n = 162) <sup>191</sup>	Sequential	53%	NA	14%	0%
	LVD	36%	NA	18%	23%
Yurdaydin <i>et al.</i> 2005 (n = 78) <sup>193</sup>	Sequential	51%	NA	54%	24%
	LVD	41%	NA	59%	53%
Sarin <i>et al.</i> 2005 (n = 75) <sup>194</sup>	Sequential	40%	40%	40%	15%
	LVD	14%	11%	16%	8%
Schalm <i>et al.</i> 2000 (n = 226) <sup>192</sup>	Sequential	50%	36%	55%	0%
	IFN	50%	22%	49%	0%
	LVD	63%	19%	63%	31%

BR, biochemical response; IFN, interferon; LVD, lamivudine; LVD-R, lamivudine resistant mutation; NA, not applicable because hepatitis B e-antigen patients are studied; SC, seroconversion; VR, virological response.

### Long-term outcome

The end-point of antiviral therapy is to prevent liver cirrhosis and HCC. Meta-analysis of five studies including 935 patients revealed that IFN treatment significantly decreased the incidence of cirrhosis with the combined risk ratio of 0.65 (95% confidence interval [CI] = 0.47–0.91).<sup>195</sup> Meta-analysis of 11 studies including 2082 patients revealed that IFN treatment significantly decreased the incidence of HCC with the combined risk ratio of 0.59 (95% CI = 0.43–0.81).<sup>195</sup> These results suggest that IFN prevents progression of liver disease to liver cirrhosis or delays the development of HCC, as long as it is within 4–7 years of follow up which is the length of follow up in these studies. Sustained response to IFN therapy was associated with increased survival.<sup>175,181,196,197</sup> To further elucidate the impact of IFN on the natural course of chronic hepatitis B, studies with larger populations followed for longer periods may be needed.

#### Consensus statement 12

- 12-1 IFN therapy prevents progression to cirrhosis or the development of HCC. (Level 1a.)  
12-2 IFN therapy is associated with improved survival. (Level 1b.)

### Adverse effects

The most frequent adverse effects are flu-like symptoms, fatigue, myelosuppression and dermal reaction at the injection site. Others include alopecia, depression and thyroid dysfunction. Less frequent but severe adverse events include interstitial pneumonitis, exacerbation of underlying autoimmune disorders, cerebral vascular events and flare of hepatitis.

### REFERENCES

- Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004; 11: 97–107.
- McMahon BJ, Alward WL, Hall DB *et al.* Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985; 151: 599–603.
- Shiffman RN, Shenkelle P, Overhage JM, Drimshaw J, Deshpande AM. Standard reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. *Ann Intern Med* 2003; 139: 493–8.
- McMahon BJ. The natural history of chronic hepatitis B virus infection. *Hepatology* 2009; 49: S45–55.
- Fattovich G. Natural history and prognosis of hepatitis B. *Semin Liver Dis* 2003; 23: 47–58.
- Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. *Science* 1993; 262: 369–70.
- Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. *Hepatology* 2007; 45: 1056–75.
- Lok AS. Chronic hepatitis B. *N Engl J Med* 2002; 346: 1682–3.
- Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 – summary of a workshop. *Gastroenterology* 2001; 120: 1828–53.
- Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. *Hepatology* 1995; 22: 1387–92.
- Hui CK, Leung N, Yuen ST *et al.* Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. *Hepatology* 2007; 46: 395–401.
- Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. *Hepatology* 1988; 8: 1130–3.
- Bortolotti F, Guido M, Bartolacci S *et al.* Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. *Hepatology* 2006; 43: 556–62.
- Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. *Am J Med* 2004; 116: 829–34.
- Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. *Ann Intern Med* 1981; 94: 744–8.
- McMahon BJ. Epidemiology and natural history of hepatitis B. *Semin Liver Dis* 2005; 25 (Suppl 1): 3–8.
- Fattovich G, Rugge M, Brollo L *et al.* Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. *Hepatology* 1986; 6: 167–72.
- Liaw YF, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. *Liver* 1984; 4: 301–6.
- Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. *Gastroenterology* 1987; 92: 1839–43.
- McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. *Ann Intern Med* 2001; 135: 759–68.
- Yuen MF, Yuan HJ, Hui CK *et al.* A large population study of spontaneous HBeAg seroconversion and acute exacerbation.

- bation of chronic hepatitis B infection: implications for antiviral therapy. *Gut* 2003; 52: 416-19.
- 22 Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 2000; 118: 554-9.
  - 23 Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. *Gastroenterology* 2002; 122: 1756-62.
  - 24 Hsu YS, Chien RN, Yeh CT *et al.* Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. *Hepatology* 2002; 35: 1522-7.
  - 25 Carman WF, Jacyna MR, Hadziyannis S *et al.* Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. *Lancet* 1989; 2: 588-91.
  - 26 Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. *Hepatology* 1999; 29: 976-84.
  - 27 Chen CH, Hung CH, Lee CM *et al.* Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. *Gastroenterology* 2007; 133: 1466-74.
  - 28 Marschenz S, Endres AS, Brinckmann A *et al.* Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. *Gastroenterology* 2006; 131: 765-80.
  - 29 Chen CH, Changchien CS, Lee CM *et al.* Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. *J Infect Dis* 2008; 198: 1634-42.
  - 30 Yuen MF, Tanaka Y, Shinkai N *et al.* Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. *Gut* 2008; 57: 98-102.
  - 31 Ikeda K, Saitoh S, Koida I *et al.* A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *Hepatology* 1993; 18: 47-53.
  - 32 Yu MW, Chang HC, Liaw YF *et al.* Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. *J Natl Cancer Inst* 2000; 92: 1159-64.
  - 33 Chen CJ, Yang HI, Su J *et al.* Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; 295: 65-73.
  - 34 Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. *Eur J Cancer Prev* 2009; 18: 26-32.
  - 35 Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. *Gastroenterology* 2003; 124: 327-34.
  - 36 Yu MW, Yeh SH, Chen PJ *et al.* Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. *J Natl Cancer Inst* 2005; 97: 265-72.
  - 37 Benvegna L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. *Gut* 2004; 53: 744-9.
  - 38 Ohnishi K, Iida S, Iwama S *et al.* The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. *Cancer* 1982; 49: 672-7.
  - 39 Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology* 2004; 127: S72-78.
  - 40 Manno M, Camma C, Schepis F *et al.* Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. *Gastroenterology* 2004; 127: 756-63.
  - 41 Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. *Gastroenterology* 2002; 123: 1084-9.
  - 42 Huo TI, Wu JC, Lee PC *et al.* Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. *Hepatology* 1998; 28: 231-6.
  - 43 Hui CK, Cheung WW, Zhang HY *et al.* Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. *Gastroenterology* 2006; 131: 59-68.
  - 44 Tanaka E, Umemura T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the World. *Clin J Gastroenterol* 2008; 1: 83-6.
  - 45 Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. *Intern Med* 2006; 45: 747-8.
  - 46 Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. *Clin Infect Dis* 2008; 47: e52-56.
  - 47 Taylor BC, Yuan JM, Shamlivan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. *Hepatology* 2009; 49: S85-95.
  - 48 Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. *Hepatol Res* 2010; 40: 14-30.
  - 49 Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. *J Hepatol* 2009; 50: 805-16.
  - 50 Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. *Dig Dis* 1992; 10: 46-52.
  - 51 Koibuchi T, Hitani A, Nakamura T *et al.* Predominance of genotype A HBV in an HBV-HIV-1 dually positive

- population compared with an HIV-1-negative counterpart in Japan. *J Med Virol* 2001; 64: 435–40.
- 52 Shibayama T, Masuda G, Ajisawa A *et al.* Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. *J Med Virol* 2005; 76: 24–32.
- 53 Kobayashi M, Arase Y, Ikeda K *et al.* Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. *J Med Virol* 2002; 68: 522–8.
- 54 Ozasa A, Tanaka Y, Orito E *et al.* Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. *Hepatology* 2006; 44: 326–34.
- 55 Sugauchi F, Orito E, Ohno T *et al.* Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. *Hepatol Res* 2006; 36: 107–14.
- 56 Suzuki Y, Kobayashi M, Ikeda K *et al.* Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol* 2005; 76: 33–9.
- 57 Matsuura K, Tanaka Y, Hige S *et al.* Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. *J Clin Microbiol* 2009; 47: 1476–83.
- 58 Sherlock S. The natural history of hepatitis B. *Postgrad Med J* 1987; 63 (Suppl 2): 7–11.
- 59 Sugiyama M, Tanaka Y, Kato T *et al.* Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. *Hepatology* 2006; 44: 915–24.
- 60 Sugiyama M, Tanaka Y, Kurbanov F *et al.* Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. *Gastroenterology* 2009; 136: 652–62. e3.
- 61 Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. *Hepatol Res* 2008; 38: 646–57.
- 62 Sato S, Suzuki K, Akahane Y *et al.* Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. *Ann Intern Med* 1995; 122: 241–8.
- 63 Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *N Engl J Med* 1991; 324: 1699–704.
- 64 Liang TJ, Hasegawa K, Rimoin N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. *N Engl J Med* 1991; 324: 1705–9.
- 65 Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. *Gastroenterology* 1993; 105: 1173–8.
- 66 Feray C, Gigou M, Samuel D, Bernuau J, Bismuth H, Brechot C. Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. *J Hepatol* 1993; 18: 119–22.
- 67 Liang TJ, Hasegawa K, Munoz SJ *et al.* Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. *J Clin Invest* 1994; 93: 550–5.
- 68 Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. *Semin Liver Dis* 2006; 26: 153–61.
- 69 Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. *Gastroenterol Clin Biol* 2009; 33: 911–15.
- 70 Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; 45: 507–39.
- 71 Chan HL, Tse CH, Mo F *et al.* High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. *J Clin Oncol* 2008; 26: 177–82.
- 72 Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. *Am J Gastroenterol* 2006; 101: 1797–803.
- 73 Chan HL, Hui AY, Wong ML *et al.* Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. *Gut* 2004; 53: 1494–8.
- 74 Sumi H, Yokosuka O, Seki N *et al.* Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. *Hepatology* 2003; 37: 19–26.
- 75 Tanaka Y, Mukaide M, Orito E *et al.* Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. *J Hepatol* 2006; 45: 646–53.
- 76 Huang Y, Wang Z, An S *et al.* Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. *J Med Virol* 2008; 80: 591–7.
- 77 Livingston SE, Simonetti JP, McMahon BJ *et al.* Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. *J Infect Dis* 2007; 195: 5–11.
- 78 Tseng TC, Kao JH. HBV genotype and clinical outcome of chronic hepatitis B: facts and puzzles. *Gastroenterology* 2008; 134: 1272–3. author reply 3.
- 79 Kew MC, Kramvis A, Yu MC, Arakawa K, Hodgkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. *J Med Virol* 2005; 75: 513–21.
- 80 Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. *J Hepatol* 1998; 28: 132–41.
- 81 Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. *Gastroenterology* 2002; 123: 1848–56.

- 82 Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. *Proc Natl Acad Sci U S A* 1986; 83: 1578-82.
- 83 Uy A, Bruss V, Gerlich WH, Köchel HG, Thomssen R. Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein. *Virology* 1986; 155: 89-96.
- 84 Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N, Matsubara K. Expression of hepatitis B virus core antigen gene in *Saccharomyces cerevisiae*: synthesis of two polypeptides translated from different initiation codons. *J Virol* 1986; 59: 176-80.
- 85 Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. *Hepatal Res* 2010; 40: 14-30.
- 86 Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. *J Infect Dis* 1997; 175: 1285-93.
- 87 Okamoto H, Tsuda F, Akahane Y *et al.* Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. *J Virol* 1994; 68: 8102-10.
- 88 Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. *J Virol* 1996; 70: 5845-51.
- 89 Parekh S, Zoulim F, Ahn SH *et al.* Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. *J Virol* 2003; 77: 6601-12.
- 90 Kosaka Y, Takase K, Kojima M *et al.* Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. *Gastroenterology* 1991; 100: 1087-94.
- 91 Karayiannis P, Alexopoulou A, Hadziyannis S *et al.* Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. *Hepatology* 1995; 22: 1628-34.
- 92 Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. *Gastroenterology* 1995; 109: 1618-23.
- 93 Laskus T, Rakela J, Persing DH. The stem-loop structure of the cis-encapsidation signal is highly conserved in naturally occurring hepatitis B virus variants. *Virology* 1994; 200: 809-12.
- 94 Liu CJ, Kao JH, Lai MY, Chen PJ, Chen DS. Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. *J Med Virol* 2004; 72: 545-50.
- 95 Pollicino T, Zanetti AR, Cacciola I *et al.* Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. *Hepatology* 1997; 26: 495-9.
- 96 Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. *Hepatology* 2001; 34: 385-94.
- 97 Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. *Gastroenterology* 1997; 113: 1976-82.
- 98 Zhang K, Imazeki F, Fukai K *et al.* Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis in relation to HBeAg and anti-HBe. *J Med Virol* 2007; 79: 683-93.
- 99 Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. *Hepatology* 1999; 29: 946-53.
- 100 Liu CJ, Chen BF, Chen PJ *et al.* Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. *J Infect Dis* 2006; 194: 594-9.
- 101 Guo X, Jin Y, Qian G, Tu H. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. *J Hepatol* 2008; 49: 718-25.
- 102 Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. *Liver Int* 2007; 27: 1356-63.
- 103 Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. *World J Gastroenterol* 2006; 12: 6620-6.
- 104 Yang HI, Yeh SH, Chen PJ *et al.* REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst* 2008; 100: 1134-43.
- 105 Fang ZL, Sabin CA, Dong BQ *et al.* HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. *Am J Gastroenterol* 2008; 103: 2254-62.
- 106 Bläckberg J, Kidd-Ljunggren K. Mutations within the hepatitis B virus genome among chronic hepatitis B patients with hepatocellular carcinoma. *J Med Virol* 2003; 71: 18-23.
- 107 Zhang KY, Imazeki F, Fukai K *et al.* Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. *Cancer Sci* 2007; 98: 1921-9.
- 108 Fang ZL, Sabin CA, Dong BQ *et al.* Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. *J Gen Virol* 2008; 89: 2882-90.



- 109 Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. *Gastroenterology* 2006; **130**: 1153–68.
- 110 Mun HS, Lee SA, Jee Y *et al.* The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C. *J Med Virol* 2008; **80**: 1189–94.
- 111 Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. *Arch Virol* 1998; **143**: 2313–26.
- 112 Zanetti AR, Tanzi E, Manzillo G *et al.* Hepatitis B variant in Europe. *Lancet* 1988; **2**: 1132–3.
- 113 Carman WF, Zanetti AR, Karayiannis P *et al.* Vaccine-induced escape mutant of hepatitis B virus. *Lancet* 1990; **336**: 325–9.
- 114 Yamamoto K, Horikita M, Tsuda F *et al.* Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. *J Virol* 1994; **68**: 2671–6.
- 115 Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. *Hepatology* 1999; **30**: 1312–17.
- 116 McMahan G, Ehrlich PH, Moustafa ZA *et al.* Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. *Hepatology* 1992; **15**: 757–66.
- 117 Carman WF, Trautwein C, van Deursen FJ *et al.* Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. *Hepatology* 1996; **24**: 489–93.
- 118 Ghany MG, Ayola B, Villamil FG *et al.* Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. *Hepatology* 1998; **27**: 213–22.
- 119 Jongerius JM, Wester M, Cuypers HT *et al.* New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. *Transfusion* 1998; **38**: 56–9.
- 120 Chemin I, Trépo C. Clinical impact of occult HBV infections. *J Clin Virol* 2005; **34** (Suppl 1): S15–21.
- 121 Torresi J, Earnest-Silveira L, Civitico G *et al.* Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. *Virology* 2002; **299**: 88–99.
- 122 Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. *Gastroenterology* 2007; **132**: 543–50.
- 123 Chu CM, Yeh CT, Tsai SL *et al.* HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. *Hepatology* 2007; **45**: 1187–92.
- 124 Illoeje UH, Yang HI, Su J *et al.* Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006; **130**: 678–86.
- 125 Yuen MF, Ng IO, Fan ST *et al.* Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. *Am J Gastroenterol* 2004; **99**: 2032–7.
- 126 Lai CL, Chien RN, Leung NW *et al.* A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998; **339**: 61–8.
- 127 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ *et al.* Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med* 2003; **348**: 800–7.
- 128 Marcellin P, Chang TT, Lim SG *et al.* Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003; **348**: 808–16.
- 129 Marcellin P, Lau GKK, Bonino F *et al.* Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg negative chronic hepatitis B. *N Engl J Med* 2004; **351**: 1206–17.
- 130 Lau GK, Piratvisuth T, Luo KX *et al.* Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2005; **352**: 2682–95.
- 131 Sherman M, Yurdaydin C, Sollano J *et al.* Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. *Gastroenterology* 2006; **130**: 2039–49.
- 132 Lai CL, Gane E, Liaw YF *et al.* Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med* 2007; **357**: 2576–88.
- 133 Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. *J Hepatol* 2003; **38**: 322–7.
- 134 Liaw YF, Sung JJ, Chow WC *et al.* Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; **351**: 1521–31.
- 135 Leung NW, Lai CL, Chang TT *et al.* Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. *Hepatology* 2001; **33**: 1527–32.
- 136 Liaw YF, Chang TT, Wu SS *et al.* Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901. *Hepatology* 2008; **48**: 706A. abstr 894.
- 137 Lok AS, Zoulim F, Locarnini S *et al.* Hepatitis B Virus Drug Resistance Working Group. *Hepatology* 2007; **46**: 254–65.
- 138 Yuan HJ, Lee WM. Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B. *Curr Mol Med* 2007; **7**: 185–97.

- 139 Chang TT, Lai CL, Chien RN *et al.* Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. *J Gastroenterol Hepatol* 2004; 19: 1276-82.
- 140 Yatsuji H, Noguchi C, Hiraga N *et al.* Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. *Antimicrob Agents Chemother* 2006; 50: 3867-74.
- 141 Gaia S, Marzano A, Smedile A *et al.* Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. *Aliment Pharmacol Ther* 2004; 20: 281-7.
- 142 Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine *in vivo*. *Hepatology* 1996; 24: 714-17.
- 143 Chayama K, Suzuki Y, Kobayashi M *et al.* Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. *Hepatology* 1998; 27: 1711-16.
- 144 Matsumoto A, Tanaka E, Rokuhara A *et al.* Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. *Hepatol Res* 2005; 32: 173-84.
- 145 Ono-Nita SK, Kato N, Shiratori Y *et al.* YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by *in vitro* full-length viral DNA transfection. *Hepatology* 1999; 29: 939-45.
- 146 Lok AS, Hussain M, Cursano C *et al.* Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. *Hepatology* 2000; 32: 1145-53.
- 147 Ono-Nita SK, Kato N, Shiratori Y *et al.* Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. *J Clin Invest* 1999; 103: 1635-40.
- 148 Delaney WE 4th, Yang H, Westland CE *et al.* The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication *in vitro*. *J Virol* 2003; 77: 11833-41.
- 149 Zollner B, Petersen J, Schafer P *et al.* Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. *Clin Infect Dis* 2002; 34: 1273-7.
- 150 Kobayashi M, Akuta N, Suzuki F *et al.* Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. *J Med Virol* 2006; 78: 60-7.
- 151 Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. *Hepatology* 2000; 31: 1318-26.
- 152 Fung SK, Chae HB, Fontana RJ *et al.* Virologic response and resistance to adefovir in patients with chronic hepatitis B. *J Hepatol* 2006; 44: 283-90.
- 153 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ *et al.* Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. *N Engl J Med* 2005; 352: 2673-81.
- 154 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ *et al.* Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology* 2006; 131: 1743-51.
- 155 Angus P, Vaughan R, Xiong S *et al.* Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. *Gastroenterology* 2003; 125: 292-7.
- 156 Lee YS, Suh DJ, Lim YS *et al.* Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. *Hepatology* 2006; 43: 1385-91.
- 157 Chen CH, Wang JH, Lee CM *et al.* Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. *Antivir Ther* 2006; 11: 771-8.
- 158 Yeon JE, Yoo W, Hong SP *et al.* Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. *Gut* 2006; 55: 1488-95.
- 159 Chang TT, Gish RG, de Man R *et al.* BEHoLD AI463022 Study Group A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006; 354: 1001-10.
- 160 Tenney DJ, Rose RE, Baldick CJ *et al.* Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology* 2009; 49: 1503-14.
- 161 Lai CL, Shouval D, Lok AS *et al.* BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006; 9 (354): 1011-20.
- 162 Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonna RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. *Antimicrob Agents Chemother* 1997; 41: 1444-8.
- 163 Colonna RJ, Rose R, Baldick CJ *et al.* Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. *Hepatology* 2006; 44: 1656-65.
- 164 Tenney DJ, Rose RE, Baldick CJ *et al.* Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. *Antimicrob Agents Chemother* 2007; 51: 902-11.
- 165 Suzuki F, Suzuki Y, Akuta N *et al.* Changes in viral loads of lamivudine-resistant mutants during entecavir therapy. *Hepatol Res* 2008; 9 (38): 132-40.
- 166 Hoofnagle JH, Peters M, Mullen KD *et al.* Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. *Gastroenterology* 1988; 95: 1318-25.

- 167 Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. *N Engl J Med* 1990; 323: 295-301.
- 168 Suzuki F, Arase Y, Akuta N et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. *J Gastroenterol* 2004; 39: 969-74.
- 169 Zhao H, Kurbanov F, Wan MB et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. *Clin Infect Dis* 2007; 44: 541-8.
- 170 Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005; 365: 123-9.
- 171 Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. *Gastroenterology* 1995; 109: 908-16.
- 172 Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. *Gastroenterology* 1993; 104: 1116-21.
- 173 Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. *Ann Intern Med* 1993; 119: 312-23.
- 174 Janssen HL, Gerken G, Carreno V et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999; 30: 238-43.
- 175 Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med* 1996; 334: 1422-7.
- 176 Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. *Gastroenterology* 1993; 105: 1833-8.
- 177 Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. *J Viral Hepat* 2004; 11: 349-57.
- 178 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1997; 26: 1338-42.
- 179 Fattovich G, Farci P, Rugge M et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. *Hepatology* 1992; 15: 584-9.
- 180 Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. *J Hepatol* 1990; 11 (Suppl 1): S133-136.
- 181 Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. *J Hepatol* 2001; 34: 306-13.
- 182 Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. *J Hepatol* 2002; 36: 263-70.
- 183 Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. *Gastroenterology* 2001; 121: 101-9.
- 184 Lampertico P, Del Ninno E, Viganò M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. *Hepatology* 2003; 37: 756-63.
- 185 Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. *J Viral Hepat* 2003; 10: 298-305.
- 186 Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. *J Hepatol* 2000; 33: 998-1002.
- 187 Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. *Hepatology* 2002; 36: 1425-30.
- 188 Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. *Am J Gastroenterol* 2006; 101: 297-303.
- 189 Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology* 2008; 135: 459-67.
- 190 Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. *Aliment Pharmacol Ther* 2006; 23: 99-106.
- 191 Shi M, Wang RS, Zhang H et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. *J Antimicrob Chemother* 2006; 58: 1031-5.
- 192 Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. *Gut* 2000; 46: 562-8.

- 193 Yurdaydin C, Bozkaya H, Cetinkaya H *et al.* Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. *J Viral Hepat* 2005; 12: 262-8.
- 194 Sarin SK, Kumar M, Kumar R *et al.* Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. *Am J Gastroenterol* 2005; 100: 2463-71.
- 195 Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. *J Viral Hepat* 2009; 16: 265-2671.
- 196 Lin SM, Sheen IS, Chien RN *et al.* Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. *Hepatology* 1999; 29: 971-5.
- 197 van Zonneveld M, Honkoop P, Hansen BE *et al.* Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004; 39: 804-10.

# Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection

Man-Fung Yuen,<sup>1,2</sup> Danny Ka-Ho Wong,<sup>1,2</sup> Cheuk-Kwong Lee,<sup>2</sup> Yasuhito Tanaka,<sup>3</sup> Jean-Pierre Allain,<sup>5</sup> James Fung,<sup>1</sup> Jennifer Leung,<sup>2</sup> Che-Kit Lin,<sup>2</sup> Masaya Sugiyama,<sup>3</sup> Fuminaka Sugauchi,<sup>4</sup> Masashi Mizokami,<sup>5</sup> and Ching-Lung Lai<sup>1</sup>

<sup>1</sup>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, and <sup>2</sup>Hong Kong Red Cross Blood Transfusion Service, Hospital Authority, Hong Kong; <sup>3</sup>Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, <sup>4</sup>Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya; <sup>5</sup>Research Center for Hepatitis and Immunology, International Medical Center of Japan Konodai Hospital, Ichikawa, Japan, and <sup>6</sup>Department of Haematology, University of Cambridge, Cambridge, United Kingdom

**Background.** Studies of the transmissibility of hepatitis B virus (HBV) in occult hepatitis B (OHB) through blood transfusion are scarce. We aimed to determine the transmissibility of HBV in blood donors with OHB through transfusion in animal and human studies.

**Methods.** Among 217,595 blood donors, 67 donors with OHB were identified. Four chimeric mice populated with human hepatocytes were inoculated with 2 donor serum samples. Serial serum and liver HBV DNA levels were measured. Forty-nine recipients of blood transfusions traced from 10 donors with OHB (9 of whom were positive for antibody to hepatitis B surface antigen [anti-HBs]) were tested for HBV infection. Homology and phylogenetic analyses between the HBV genomic sequences of donors and recipients were performed.

**Results.** Serum HBV DNA was detectable ( $10^4$  copies/mL) in 1 mouse at weeks 5 and 7 after inoculation. Total HBV DNA and HBV replication template (covalently closed circular DNA) and hepatitis B core antigen were detected in the mouse liver. After transfusion, 45 recipients (91.8%) had no HBV infection (ie, they tested negative for hepatitis B surface antigen and HBV DNA). Four tested positive for HBV DNA. In 3 recipients, 83%–86% homology and distant phylogenetic relatedness with their donor HBV excluded transmission through transfusion. The remaining recipient HBV had 95% sequence homology with her donor HBV, compatible with acquisition of HBV infection from the transfusion. High anti-HBs levels in 7 other recipients suggested recent transfusion-related HBV immune response.

**Conclusions.** OHB donor blood infectivity was shown in our animal and human studies. However, the risk of HBV transmission in humans was low, especially from blood products obtained from donors with OHB who were anti-HBs positive.

Occult hepatitis B (OHB) virus infection is defined as having detectable hepatitis B virus (HBV) DNA in the serum or livers of subjects who test negative for the hepatitis B surface antigen (HBsAg). Owing to the

extremely low serum HBV DNA level (usually <100 IU/mL) [1], which requires highly sensitive assays to confirm the diagnosis, accurate data on the prevalence and transmissibility of OHB are very limited. The latter issue is of particular importance in improving transfusion safety. Posttransfusion acute hepatitis B has been reported to occur at a rate of 0.9% [2], even after the implementation of serological screening for HBV.

Current information on the transmissibility of OHB through transfusion mainly relies on a few case series in which the possible link has not been clearly established by strict viral sequence comparisons between the HBV strains in the donors and the recipients. OHB is not

Received 6 September 2010; accepted 17 December 2010.

<sup>1</sup>M.F.Y. and D.K.H.W. contributed equally for the study.

Correspondence: Man-Fung Yuen, MD, Dept of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd, Hong Kong (mfyuen@hkucc.hku.hk).

**Clinical Infectious Diseases** 2011;52(5):624–632

© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

1058-4838/2011/525-0001\$37.00

DOI: 10.1093/cid/ciq247

a common entity in most countries, with a typical prevalence of <1% [3–6]. Identification of a blood donor with OHB requires considerable time for performance of nucleic acid testing (NAT) followed by extremely sensitive polymerase chain reaction (PCR) assays. These also require a high expenditure on resources. Once the donated blood is identified as OHB positive, it is discarded for obvious ethical reasons. Retrospective tracing studies are difficult to conduct because of the time lag between identification of the OHB products and contact of recipients. In addition, in areas where HBV is highly endemic, a large proportion of the population would have been naturally infected with or vaccinated against HBV.

We conducted the present study to determine the transmissibility of HBV from donors with OHB in 2 parts: (1) a chimeric mice study, to determine whether serum obtained from donors with OHB was infectious; and (2) a recipient look-back study to determine whether OHB-containing blood components were transfusion-transmissible in human recipients.

## SUBJECTS AND METHODS

### Subjects

The present study recruited all healthy blood donors found to have OHB during the period from 1 April 2007 through 31 January 2009 in the Hong Kong Red Cross Blood Transfusion Service. These subjects were identified by testing their blood samples for HBsAg (Prism HBsAg; Abbott Laboratories) and NAT for HBV DNA (Procleix Trigis system; Chiron; 95% detection limit, 12.2 IU/mL). All HBsAg-negative and HBV DNA-positive samples had HBV DNA levels measured by real-time PCR in the Mx4000 Multiplex Quantitative PCR System (Stratagene), using primers and 6-carboxyfluorescein (FAM)-labeled TaqMan probe targeting to conserved regions in the HBV surface gene, as described previously [7].

Of 217,595 donors, 67 subjects with OHB (0.031%) were identified. They were all negative for antibodies to human immunodeficiency virus and hepatitis C virus. Of these 67 subjects with OHB, 44 consented to participate in this study for the following additional tests: determination of the HBV DNA level, with the Artus HBV RG assay (Qiagen), which has a linear range of detection of 1.1 IU/mL to  $>4 \times 10^9$  IU/mL; assessment for antibodies to HBsAg (anti-HBs) and hepatitis B core antigen (anti-HBc; Roche Diagnostics); the chimeric mice study; and the recipient look-back study with HBV genome sequencing.

### Chimeric Mice Study

Two donor samples indicating OHB—1 with undetectable anti-HBs and 1 with anti-HBs titer  $\geq 10$  IU/L (conventionally taken as “protective” against HBV infection)—were used to inoculate 4 chimeric mice (2 mice for each sample). These were severe

combined immunodeficiency (SCID) mice transgenic for the urokinase-type plasminogen activator gene (uPA+/+/SCID+/+ mice), with the livers replaced by human hepatocytes [8] (Phoenix Bio). Human serum albumin produced by human hepatocytes was measured by enzyme-linked immunosorbent assay (Bethyl Laboratories). One hundred microliters of the donor serum, after 10-fold concentration, were intravenously injected into the mice. Serum samples were taken weekly from the mice from week 4–9 after inoculation. At week 9, the mice were killed for liver immunostaining and intrahepatic HBV DNA and covalently closed circular DNA (cccDNA) measurements. HBV DNA levels were quantified by real-time PCR targeting a small S region [9], with the sensitivity of 1000 copies/mL (200 IU/mL). The cccDNA, replicative template of HBV was quantified by real-time detection-PCR using a set of conserved primers [10]. Animal protocols were performed in accordance with guidelines for animal experimentation.

Liver sections were blocked with antibody diluent (Dako), incubated with rabbit anti-HBc (Dako) at room temperature for 1 h, washed in phosphate-buffered saline, and then incubated with goat anti-rabbit immunoglobulin G conjugated with Cy3 (Chemicon international) or goat anti-human albumin labeled with fluorescein isothiocyanate (Bethyl Laboratories). Sections were washed with phosphate-buffered saline and observed in a fluorescent microscope (Eclipse E800M; Nikon).

### Look-Back Study

Data tracing of all recipients of blood components from the 44 donors with OHB were retrieved from the database of the Hong Kong Red Cross Blood Transfusion Service. Data obtained included sex, age, the date and type of blood products transfused, indication for transfusion, the nature of the illness, and HBsAg status prior to the targeted (look-back) transfusion.

Two genomic regions (pre-S and core) were sequenced from the serum of the 44 donors with OHB. In brief, HBV DNA was extracted from their serum samples using the QIAamp MinElute Virus Vacuum Kit (Qiagen). The pre-S and core regions were amplified by nested PCR, and the 2 resulting amplicons, covering the pre-S and core regions at nt 2814–237 and 1607–2385, respectively, were sequenced bi-directionally. These 2 most variable HBV regions [1, 11] were used for homology and phylogenetic comparisons between paired donors and recipients strains. Thirty-one of the 44 donors with OHB had successful viral sequencing results at either the pre-S or core regions. Recipients of transfusions from these 31 donors with OHB were contacted. HBsAg, anti-HBs, anti-HBc, and HBV DNA levels (determined as described above) were checked in recipients who consented to take part in the study. For recipients with detectable HBV DNA, the pre-S and core regions were also sequenced by PCR. Viral sequence homology of the donor and recipient

strains was performed using the CLUSTAL X program [12]. Genetic distances were estimated by the maximum composite likelihood method, and phylogenetic trees were constructed by using the neighbor-joining method, using the Molecular Evolutionary Genetics Analysis (MEGA) software, version 4 [13]. Bootstrap resampling tests were performed 1000 times to confirm the reliability of the phylogenetic tree, and values >70% were considered to be significant [14, 15]. The presence of the common surface gene mutants (G145R) were determined by PCR sequencing using primers spanning the HBV surface gene at nucleotides 426–600 (amino acid residues, 134–148).

The study was approved by the Institutional Review Board of the University of Hong Kong and the Hospital Authority Hong Kong West Cluster. Written, informed consent was obtained from both the donors and recipients. For those recipients aged <18 years, consent was obtained from parents.

### Statistical Analysis

The present study was descriptive in nature. Continuous variables were expressed as mean values with standard deviations and ranges.

## RESULTS

Forty-four of the 67 identified OHB donors consented to have additional blood samples obtained for further studies. Thirty-three donors (75%) had anti-HBs levels  $\geq 10$  IU/L. The donors' demographic characteristics, serologic parameters, and HBV DNA levels are listed in Table 1.

### Chimeric Mice Study

Serum samples from 2 randomly selected donors (Rx5 and Rx7) with HBV DNA levels of 9.1 and 11.0 IU/mL, respectively, and anti-HBs levels of 34 IU/L and below the detection limit, respectively, were inoculated into 4 mice (2 mice for each serum sample at the DNA amount of 52.8 and 63.8 copies). Serum HBV DNA was detectable in 1 mouse (PXB 8–22), which was inoculated with serum with undetectable anti-HBs from donor Rx7 at weeks 5 and 7 ( $2.4 \times 10^4$  and  $2.0 \times 10^4$  copies/mL, respectively). The other 3 mice had no detectable serum HBV DNA up to 9 weeks. Total DNA and cccDNA (0.0458 and 0.0103 copies/cells, respectively) were detected in the liver of the PXB 8–22 mouse, whereas HBV DNA and cccDNA were not detectable in the livers of the other 3 mice. The immunofluorescent microscopy for hepatitis B core antigen (HBcAg) and human albumin in the liver tissues showed that the human hepatocytes expressed HBcAg (Figure 1).

### Look-Back Study

Thirty-one donors with OHB had successful viral sequence generation. Two hundred seventy-two recipients who had


**Table 1. Demographic Characteristics, Serologic Parameters, and Hepatitis B Virus (HBV) DNA Levels for 44 Donors with Occult Hepatitis B Infection**

Characteristic	Value
Ratio of male to female subjects	32:12
Age, years	
Mean $\pm$ SD	46.9 $\pm$ 11.9
Range	16.8–61.2
HBV DNA level	
No. (%) of donors with an HBV DNA level <1.1 IU/mL (%)	26 (59.1)
No. (%) of donors with an HBV DNA level $\geq 1.1$ IU/mL (%)	18 (40.9)
Mean	15.8
SD	45.5
Range	1.1–196.6
G145R mutations (the vaccine escape mutants), no. (%) of donors	0 (0)
Anti-HBs level	
No. (%) of donors with anti-HBs $\geq 10$ IU/mL	33 (75%)
Titer	
Mean $\pm$ SD	217.4 $\pm$ 309.9
Range	11.1 to >1000
Anti-HBc	
No. of donors with positive anti-HBc	42 (95.5%)

**NOTE.** All samples positive for antigen to hepatitis B core antigen (anti-HBc) samples were of immunoglobulin G subtype. Anti-HBs, antibody to hepatitis B surface antigen.

received blood products within 3 years from these 31 donors with OHB were identified. Forty-nine recipients from 10 donors were successfully traced and consented to participate in the study. The remaining 223 recipients were not being able to undergo further investigations because they could not be contacted ( $n = 46$ ), refused to participate in the study ( $n = 30$ ), or died ( $n = 147$ ). The causes of death for these 147 subjects were traced successfully. Only 16 deaths (10.9%) were liver related (3 recipients died of hepatitis C virus–related cirrhosis and/or liver cancer, and 13 recipients were known to have chronic HBV infection before transfusion and died of HBV related cirrhosis and/or liver cancer). None died because of fulminant HBV infection.

Detailed demographic characteristics and clinical, serological, and virological parameters of the 10 donors with OHB and the 49 recipients (ratio of male to female subjects, 24:25) are listed in Table 2. All 10 donors were repeated donors. The sample with which OHB was first diagnosed by NAT is defined as the “index sample”; the sample from the donation received by the 49 recipients is the “look-back sample” (HBV DNA levels were available in some cases); the sample taken when they were recalled for further study is the “sample at the time of further investigations.” The median age of the recipients was 49.9 years



**Figure 1.** Staining for hepatitis B core antigen (HBcAg). In the PXB 8-22 mouse, staining for HBcAg was confined to areas where mouse liver had been replaced for human hepatocytes (the areas stained for human albumin). Co-localization of HBcAg and human hepatocytes (~40% of total human hepatocytes at this area) was demonstrated by double-staining for HBcAg and human albumin, whereas no merged stain was found in the PXB 8-20 mouse.

(range, 3.1–87.4 years). Fifteen recipients were immunocompromised because they had undergone organ transplantation with immunosuppressive therapy, had a hematologic malignancy, or had end-staged renal failure.

Twenty recipients (40.8%) were positive for immunoglobulin G anti-HBc (15 with anti-HBs) (Table 2). Thirteen (26.5%) had detectable anti-HBs levels but no anti-HBc, suggesting HBV vaccination. Nine of these 13 recipients were aged <35 years. Both anti-HBc and anti-HBs were undetectable in 16 recipients (32.7%), who were considered to be susceptible to HBV infection but noninfected. Only the 15 recipients carrying both anti-HBc and anti-HBs were considered possibly HBV infected by transfusion, and among these, 2 (Rx69 and Rx96) were found to be HBV DNA positive (HBV DNA level, 9.3 and 14 IU/mL, respectively), indicating an OHB carrier state. The viral sequence homology between the recipients and donors HBV was 83% and 95%, respectively, with values confirmed by the phylogenetic analyses (Figure 2). Another 2 recipients (Rx42 and Rx70) tested positive for HBsAg with detectable HBV DNA, indicating chronic HBV carriage (one was immunocompromised [viral load,  $7.3 \times 10^7$  IU/mL]; the other had a viral load of 33

IU/mL). The viral sequence homology for these 2 recipients' and donors' HBV was only 88% and 86%, respectively, with values confirmed by the phylogenetic analyses (Figure 2). The liver biochemistries of these 4 recipients were all normal.

Of the remaining 45 recipients, 16 had undetectable anti-HBc and anti-HBs; 3 were positive for anti-HBc, but anti-HBs was undetectable; 13 had undetectable anti-HBc but were positive for anti-HBs; and 13 were positive for both anti-HBc and anti-HBs (Table 2). Of the 26 recipients with positive anti-HBs, 8 had moderately high anti-HBs titers ( $\geq 200$  IU/mL). Two (Rx39 and Rx66) of these 8 recipients were negative for anti-HBc, and 6 (Rx40, Rx47, Rx67, Rx71, Rx95, and Rx97) were positive for anti-HBc. One 12-year-old recipient (Rx66) had an anti-HBs titer of 412 IU/L tested 26 months after transfusion. The other 7 recipients (age, 47–75 years) had anti-HBs levels between 299 and >1000 IU/L tested 20–52 months after transfusion. These 7 recipients received blood components carrying HBV DNA in all tested donations (5–27 IU/mL) from 4 donors (Rx36, Rx34, Rx58, and Rx15). Only 6 of the 27 recipients of transfusions from these 4 donors remained susceptible and noninfected (ie, negative for both anti-HBc and anti-HBs).


There were 223 recipients for whom further investigations were not performed. Twenty-four were HBsAg positive and 199 had unknown HBsAg status before transfusions. Of these 199 recipients, 24 underwent HBsAg testing after transfusions. Twenty-three of these 24 recipients were negative for HBsAg. The remaining recipient (who died of lung cancer 4 months after the transfusion) was positive for HBsAg.

## DISCUSSION

In the present study, we demonstrated in the chimeric mice that serum obtained from donors with OHB with undetectable anti-HBs could be infectious. Serum HBV DNA was detected in 1 infected mouse, and more importantly, intrahepatic HBV DNA, cccDNA (the viral template in hepatocyte nucleus for viral transcription), and HBcAg (the viral protein) were found in the human hepatocytes of the mouse liver. On the contrary, the sample with positive anti-HBs titer did not infect the mice. Additional animal studies using chimeric mice model should be performed with more samples from donors with OHB, with and without anti-HBs, to confirm our preliminary finding.

It has been shown that anti-HBc-positive blood products can cause acute HBV infection in recipients [16–19]. The infectivity of anti-HBs-positive blood products is still not well defined in humans [20]. Of the 49 recipient follow-up samples, 4 were positive for HBV DNA. Two were HBsAg positive, indicating chronic hepatitis B carriage; 2 were HBsAg negative, indicating OHB. The viral sequence homology of only 83%–86%, confirmed by the distant phylogenetic relatedness between donor and recipient strains, excluded a transfusion origin in 3 of these





**Figure 2.** Phylogenetic analysis of the pre-S or core sequences of the 4 recipients with detectable HBV DNA (A, Rx42; B, Rx69; C, Rx70; and D, Rx96) and their corresponding donors. Sequences from the recipients and donors (boxed and in bold-face fonts) were subjected to phylogenetic analysis, along with the same pre-S or core regions from GenBank reference HBV sequences of various HBV genotypes (10 each of genotypes B and C, the 2 most common genotypes in Hong Kong, and 2 each of genotypes A, D, E, F, G, and H) and a reference woolly monkey hepatitis B virus (WMHBV) sequence. Sequences retrieved from the GenBank are designated by their accession numbers. The figures on the nodes indicate the percentage of occurrences by bootstrap analysis of 1000 replicates. Only bootstrap values >70% are shown. The length of the horizontal bars indicates the number of nucleotide substitutions per site.

**Table 2. Detailed Demographic Characteristics and Serological and Virological Data for the Donor and Recipient Pairs**

Donor	Donor index sample HBV markers	Look-back sample HBV DNA, IU/mL	Donor sample at the time of further investigations	Recipient	Blood component transfused	Recipient HBV markers	Transfusion-follow-up sample collection (months)	HBV status							
Code	Sex/age, years	Anti-HBc (u/L)	Anti-HBs (u/L)	Anti-HBc (u/L)	HBV DNA (IU/mL)	Sex/age, years	Anti-HBc (u/L)	Anti-HBs (u/L)	HBV DNA (IU/mL)	HBV status					
Rx15	M/59	Pos	Neg <sup>a</sup> 16	Pos	32.7	UD <sup>b</sup>	Rx83	M/70	No	RC <sup>c</sup>	Neg	Neg	UD	35	Susceptible
							Rx87	M/72	Yes	Plt	Pos	>1000	UD	33	Recovered HBV <sup>a</sup>
							<b>Rx69</b>	<b>F/76</b>	<b>No</b>	<b>RC</b>	<b>Pos</b>	<b>52</b>	<b>9.3</b>	<b>25</b>	<b>OHB</b>
							Rx73	F/77	No	RC	Pos	87	UD	49	Recovered HBV
							Rx77	F/58	Yes	FFP	Neg	Neg	UD	48	Susceptible
							Rx95	F/52	No	Plt	Pos	299	UD	38	Recovered HBV <sup>a</sup>
							Rx82	F/34	No	FFP	Neg	102	UD	32	Vaccinated
							Rx76	F/69	No	Plt	Pos	175	UD	49	Recovered HBV
							Rx100	M/6	No	Plt	Neg	Neg	UD	51	Susceptible
							<b>Rx96</b>	<b>F/51</b>	<b>No</b>	<b>RC</b>	<b>Pos</b>	<b>30</b>	<b>14</b>	<b>60</b>	<b>OHB</b>
							Rx83	M/19	No	Plt	Neg	Neg	UD	50	Susceptible
							Rx84	F/22	No	RC	Neg	131	UD	46	Vaccinated
							Rx85	F/59	Yes	Plt	Pos	22	UD	52	Recovered HBV
							Rx49	F/46	Yes	Plt	Neg	Neg	UD	44	Susceptible
Rx28	M/48	Pos	30	Pos	80.1	2.79	Rx47	F/75	No	RC	Pos	367	UD	20	Recovered HBV <sup>a</sup>
Rx34	M/58	Pos	38	Pos	80.5	4.79	Rx46	F/63	No	RC	Pos	Neg	UD	23	Recovered HBV
							Rx45	M/4	Yes	Plt	Neg	Neg	UD	24	Susceptible
							Rx92	M/22	No	RC	Neg	64	UD	34	Vaccinated
Rx24	F/48	Pos	430	Pos	866.5	UD	Rx99	M/3	No	FFP	Neg	Neg	UD	36	Susceptible
							Rx91	M/65	No	Plt	Neg	14	UD	47	Vaccinated
							Rx75	F/35	No	FFP	Neg	Neg	UD	63	Susceptible
							Rx81	F/60	No	RC	Neg	17	UD	33	Vaccinated
Rx19	M/50	Pos	19	Pos	75.4	UD	Rx102	M/6	No	FFP	Neg	54	UD	23	Vaccinated
							Rx74	M/57	No	FFP	Neg	Neg	UD	40	Susceptible
							Rx98	F/31	No	RC	Neg	74	UD	31	Vaccinated
							<b>Rx70</b>	<b>F/55</b>	<b>No</b>	<b>RC</b>	<b>Pos</b>	<b>Neg</b>	<b>33</b>	<b>23</b>	<b>CHB</b>
							Rx68	F/87	No	Plt	Pos	137	UD	46	Recovered HBV
Rx23	F/46	Pos	39	Pos	85.5	1.81	Rx94	M/60	No	RC	Neg	Neg	UD	25	Susceptible
Rx36	M/61	Pos	18	Pos	67.2	UD	Rx39	M/53	No	RC	Neg	>1000	UD	48	Vaccinated <sup>a</sup>
							Rx66	M/12	Yes	Plt	Neg	412	UD	26	Vaccinated
							Rx40	M/47	Yes	FFP	Pos	>1000	UD	39	Recovered HBV <sup>a</sup>
							Rx44	M/48	Yes	Plt	Pos	Neg	UD	43	Recovered HBV

**Table 2.** (Continued)

Donor	Donor index sample HBV markers	Look-back sample HBV DNA, IU/mL	Donor sample at the time of further investigations	Recipient	Blood component transfused	Recipient HBV markers	Transfusion-follow-up sample collection (months)	HBV status
		27		Rx50 M/17 No	RC	Neg	19	Vaccinated
Rx33 F/59	Pos Neg UD	UD	Pos 85.2 UD	Rx43 F/42 Yes	FFP	Pos	41	Recovered HBV
		UD		Rx38 F/50 Yes	RC	Neg	15	Susceptible
				Rx41 M/20 No	RC	Neg	22	Vaccinated
				<b>Rx42 F/38 Yes</b>	<b>Plt</b>	<b>Pos</b>	<b>48</b>	<b>CHB + HBV reactivation</b>
Rx58 M/56	Pos Neg 8.5		Pos 24.5 1.12	Rx48 M/53 Yes	RC	Pos	52	Recovered HBV
		17		Rx67 M/56 Yes	Plt	Pos	52	Recovered HBV <sup>a</sup>
				Rx90 F/30 No	RC	Pos	15	Recovered HBV
				Rx89 F/29 No	RC	Neg	11	Vaccinated
				Rx88 M/41 No	Plt	Neg	39	Susceptible
				Rx71 F/49 No	Plt	Pos	32	Recovered HBV <sup>a</sup>
Rx63 M/49	Pos Neg 11		Pos Neg UD	Rx78 F/50 No	CRYO	Neg	38	Vaccinated
		8		Rx87 M/54 Yes	RC	Pos	19	Recovered HBV
		26		Rx72 M/66 No	RC	Neg	16	Susceptible
		UD		Rx86 F/68 No	Plt	Neg	25	Susceptible
				Rx80 M/40 No	RC	Neg	35	Susceptible
				Rx79 M/34 Yes	RC	Neg	30	Susceptible

**NOTE.** **Bolded** recipient data indicates those found HBV DNA positive in the follow-up sample. CRYO, cryoprecipitate; FFP, fresh frozen plasma; HBV, hepatitis B virus; Neg, antibody to hepatitis B surface antigen (anti-HBs) titer of <10 IU/mL; OHB, occult hepatitis B; Plt, platelet concentrate; RC, red cell concentrate; UD, samples with HBV DNA detectable by nucleic acid tests but not quantifiable by the real-time polymerase chain reaction assays, either with total absence of signal or below the lower limit of detection.

<sup>a</sup> Recipients suspected of having exposure/reexposure to HBV after receiving the blood products from donors with OHB as suggested by a high anti-HBs titer (>200 IU/mL).

4 cases. One of the 3 recipients (Rx42) was likely to have experienced HBV reactivation after receiving chemotherapy for non-Hodgkin lymphoma. For the fourth recipient (Rx96), who was negative for HBsAg, with 95% homology in the highly variable pre-S genomic between the donor and recipient HBV (Figure 2), it is probable that this immunocompetent recipient acquired the HBV infection through the blood transfusion from a donor with OHB who had undetectable anti-HBs titer in the index sample and low titer (32.7 IU/L) in the sample at the time of further investigations. Discounting the 3 recipients who were probably infected with HBV before transfusion, transmission of HBV resulting in chronic HBV disease was possible but uncommon (1 [2.2%] of 46 recipients). This may be an underestimation, because 13 of the recipients were positive for anti-HBs but negative for anti-HBc, possibly because of previous HBV vaccination. The chronic HBV disease rate for the remaining 33 recipients who were susceptible to HBV infection would therefore be 3.0% (1 of 33 recipients).

Moderately high anti-HBs levels ( $\geq 200$  IU/mL) were found in 8 recipients (Table 2). One 12-year-old recipient (Rx66) with an anti-HBs titer of 412 IU/mL might have the high titer because of comparatively recent HBV vaccination during childhood. The high anti-HBs levels in the remaining 7 adult recipients (age,  $>45$  years) in samples collected 20–52 months after transfusion with blood components from 4 donors was suggestive of a relatively recent anti-HBs immune response secondary to exposure or re-exposure to HBV. (Of the 4 donors, 2 had undetectable anti-HBs in the index samples; all 4 were positive for anti-HBs at the time of additional investigations for the present study). The recent anti-HBs immune response is compatible with the transfused blood products carrying either circulating viral particles or very low level of the otherwise undetectable free HBsAg. Although not directly indicative of infectivity, it constitutes supportive evidence of potential infectivity of HBV DNA-positive blood products even in the presence of anti-HBs. Future studies correlating the detection of HBV DNA over time with respect to the timing of increase of anti-HBs levels in recipients are required to verify this hypothesis.

Nevertheless, the relative rarity of HBV transmission from donors with OHB held true for different scenarios. These included recipients who were children or elderly (4 recipients were aged  $<7$  years, 1 was aged 12 years, and 10 were aged  $>65$  years in the present study) (Table 2). Of the 15 immunocompromised recipients, none acquired HBV from transfusion (except 1 who had probably OHB before transfusion, with reappearance of HBsAg after chemotherapy, suggesting reactivation) [21].

This low infectivity may only be applicable to donors with OHB who are positive for anti-HBs (75% of all 44 donors [Table 1] and 90% of the 10 donors in the donor-recipient pairs [Table 2] were positive for anti-HBs). According to another study [22], more than one-half (57.8%) of subjects with OHB

were anti-HBs positive. It has been suggested that the risk of HBV transmission is low for blood products from anti-HBs-positive donors with OHB [23, 24]. A recent study reported a case of HBV transmission from an anti-HBs positive donor to two recipients when the low level of anti-HBs was insufficient to neutralize an increased level of HBV DNA [25].

The present study has 2 limitations. First, 147 recipients had died, making a complete recipient-tracing not possible. However, according to data on the causes of death, it appeared unlikely that the deaths were related to the transfusions. Second, clinical information with regard to the disease status, including liver function tests and liver histology, was not addressed in the present study. However, those were studied in detail in a previous study of ours: subjects with OHB subjects have normal liver function test results and nearly normal liver histology findings [26].

In conclusion, blood taken from donors with OHB was shown to be potentially infectious in our animal and human studies. However, the risk of chronic hepatitis B transmission through transfusion of blood donated by anti-HBs-positive donors with OHB in human remained low.

### Acknowledgments

We are indebted to all the involved staff of donor centers of Hong Kong Red Cross Blood Transfusion Service for their assistance in conducting the study.

**Financial Support.** The study was supported by General Research Fund, Research Grants Council, Hong Kong (reference number 781108M) and a grant-in-aid from the Ministry of Health, Labour and Welfare of Japan, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

**Potential conflicts of interest.** M.-F.Y. has served on the speakers' bureau or has given lectures at GSK and BMS.C.-L.L. has received institutional grant support from LG Life Sciences and FibroGen and has served on the speakers' bureau or given lectures to BMS and Gilead Sciences Europe. All other authors: no conflicts.

### References

- Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. *Blood Transfus* 2009; 7:174–82.
- Liu CJ, Lo SC, Kao JH, et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. *J Hepatol* 2006; 44:39–46.
- Song EY, Yun YM, Park MH, Seo DH. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. *Intervirol* 2009; 52:57–62.
- Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. *Transfusion* 2007; 47:74–9.
- Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. *Gastroenterology* 2008; 135:1192–9.
- Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. *Gastroenterology* 2004; 126:1750–8.
- Allain JP, Candotti D, Soldan K, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. *Blood* 2003; 101: 2419–25.